Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCV2 baculovirus vector inactivated vaccine (CP08 strain)
- Development stage
- Unknown
- Lead developer
- Youbang Pharmaceutical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a recombinant baculovirus vector-based inactivated vaccine developed by Youbang Pharmaceutical (also known as Uni-Bio) for the prevention of Porcine Circovirus Type 2 (PCV2) associated diseases in swine. The vaccine utilizes the CP08 strain and is produced using a baculovirus expression system to generate PCV2 capsid antigens. These antigens are then inactivated and formulated to elicit protective immunity against PCV2, which is the primary causative agent of post-weaning multisystemic wasting syndrome (PMWS) and other related porcine circovirus diseases. It is an approved veterinary biologic in China, designed to mitigate the significant economic losses caused by PCV2 in the global pig industry.
- Other names
- 猪圆环病毒2型杆状病毒载体灭活疫苗(CP08株)Porcine circovirus type 2 baculovirus vector inactivated vaccine (CP08 strain)PCV2 recombinant vector vaccinePCV-2 recombinant vector vaccinePCV 2 recombinant vector vaccine
02
Targets
PCV2 Cap (Porcine circovirus type 2 capsid protein)
Beyond the preview
Go deeper on PCV2 baculovirus vector inactivated vaccine (CP08 strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCV2 baculovirus vector inactivated vaccine (CP08 strain).